Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 7 » Issue 1
Neuropsychiatric Disease and Treatment
ISSN: 1178-2021
- View all (3975)
- Volume 19, 2023 (118)
- Volume 18, 2022 (272)
- Volume 17, 2021 (351)
- Volume 16, 2020 (325)
- Volume 15, 2019 (353)
- Volume 14, 2018 (354)
- Volume 13, 2017 (333)
- Volume 12, 2016 (367)
- Volume 11, 2015 (340)
- Volume 10, 2014 (275)
- Volume 9, 2013 (223)
- Volume 8, 2012 (74)
- Volume 7, 2011 (87)
- Volume 6, 2010 (90)
- Volume 5, 2009 (65)
- Volume 4, 2008 (128)
- Volume 3, 2007 (105)
- Volume 2, 2006 (70)
- Volume 1, 2005 (45)
Archive: Volume 7, 2011
- Issue 1 (82)
- Supplement 1 (5)
Attention deficits in Japanese multiple sclerosis patients with minor brain lesion loads
Takeda A, Nakajima M, Kobayakawa M, Tsuruya N, Koyama S, Miki T, Kawamura M
Neuropsychiatric Disease and Treatment 2011, 7:745-751
Published Date: 16 December 2011
The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies
Aagaard L, Hansen EH
Neuropsychiatric Disease and Treatment 2011, 7:729-744
Published Date: 16 December 2011
Rapid improvement of depressive symptoms in suicide attempters following treatment with milnacipran and tricyclic antidepressants – a case series
Kirino E, Gitoh M
Neuropsychiatric Disease and Treatment 2011, 7:723-728
Published Date: 14 December 2011
Association between obstructive sleep apnea (OSA) and depression and the effect of continuous positive airway pressure (CPAP) treatment
El-Sherbini AM, Bediwy AS, El-Mitwalli A
Neuropsychiatric Disease and Treatment 2011, 7:715-721
Published Date: 13 December 2011
Pregnancy is associated with psychiatric symptoms in a low-income countryside community of Brazil
Dias FMV, Junior CSD, Franco GC, Teixeira AL, Ribeiro AM
Neuropsychiatric Disease and Treatment 2011, 7:709-714
Published Date: 30 November 2011
Corrigendum
Sailasuta N, Harris K, Tran T, Ross B
Neuropsychiatric Disease and Treatment 2011, 7:707-708
Published Date: 25 November 2011
Exploration of sex differences in Rhes effects in dopamine mediated behaviors
Quintero GC, Spano D
Neuropsychiatric Disease and Treatment 2011, 7:697-706
Published Date: 17 November 2011
Comparative study of treatment continuation using second-generation antipsychotics in patients with schizophrenia or schizoaffective disorder
Azekawa T, Ohashi S, Itami A
Neuropsychiatric Disease and Treatment 2011, 7:691-695
Published Date: 17 November 2011
Life satisfaction in patients with chronic pain – relation to pain intensity, disability, and psychological factors
Stålnacke BM
Neuropsychiatric Disease and Treatment 2011, 7:683-689
Published Date: 16 November 2011
Clobazam as an adjunctive therapy in treating seizures associated with Lennox–Gastaut syndrome
Leahy JT, Chu-Shore CJ, Fisher JL
Neuropsychiatric Disease and Treatment 2011, 7:673-681
Published Date: 11 November 2011
A large pharmacy claims-based descriptive analysis of patients with migraine and associated pharmacologic treatment patterns
Muzina DJ, Chen W, Bowlin SJ
Neuropsychiatric Disease and Treatment 2011, 7:663-672
Published Date: 11 November 2011
Predisposition for borderline personality disorder with comorbid major depression is associated with that for polycystic ovary syndrome in female Japanese population
Kawamura S, Maesawa C, Nakamura K, Nakayama K, Morita M, Hiruma Y, Yoshida T, Sakai A, Masuda T
Neuropsychiatric Disease and Treatment 2011, 7:655-662
Published Date: 1 November 2011
Brain activity modification produced by a single radioelectric asymmetric brain stimulation pulse: a new tool for neuropsychiatric treatments. Preliminary fMRI study
Rinaldi S, Fontani V, Castagna A
Neuropsychiatric Disease and Treatment 2011, 7:649-654
Published Date: 28 October 2011
Polypharmacy or medication washout: an old tool revisited
Hoffman DA, Schiller M, Greenblatt JM, Iosifescu DV
Neuropsychiatric Disease and Treatment 2011, 7:639-648
Published Date: 20 October 2011
Antianxiety medications for the treatment of complex agoraphobia: pharmacological interventions for a behavioral condition
Perna G, Daccò S, Menotti R, Caldirola D
Neuropsychiatric Disease and Treatment 2011, 7:621-637
Published Date: 19 October 2011
Clinical utility of the risperidone formulations in the management of schizophrenia
Madaan V, Bestha DP, Kolli VB, Jauhari S, Burket RC
Neuropsychiatric Disease and Treatment 2011, 7:611-620
Published Date: 18 October 2011
Current management of obsessive and phobic states
Goljevscek S, Carvalho LA
Neuropsychiatric Disease and Treatment 2011, 7:599-610
Published Date: 30 September 2011
A comprehensive review of the literature on epilepsy in selected countries in emerging markets
Angalakuditi M, Angalakuditi N
Neuropsychiatric Disease and Treatment 2011, 7:585-597
Published Date: 29 September 2011
Neuroimaging in eating disorders
Jáuregui-Lobera I
Neuropsychiatric Disease and Treatment 2011, 7:577-584
Published Date: 29 September 2011
Galantamine treatment in Alzheimer's disease: response and long-term outcome in a routine clinical setting
Wallin ÅK, Wattmo C, Minthon L
Neuropsychiatric Disease and Treatment 2011, 7:565-576
Published Date: 30 September 2011
The management of schizophrenia: focus on extended-release quetiapine fumarate
Peuskens J
Neuropsychiatric Disease and Treatment 2011, 7:549-564
Published Date: 21 September 2011
Oral glycopyrrolate for the treatment of chronic severe drooling caused by neurological disorders in children
Evatt ML
Neuropsychiatric Disease and Treatment 2011, 7:543-547
Published Date: 20 September 2011
Retrospective chart review of a referenced EEG database in assisting medication selection for treatment of depression in patients with eating disorders
Greenblatt JM, Sussman C, Jameson M, Yuan L, Hoffman DA, Iosifescu DV
Neuropsychiatric Disease and Treatment 2011, 7:529-541
Published Date: 9 September 2011
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
Warnke C, Stüve O, Hartung HP, Fogdell-Hahn A, Kieseier B
Neuropsychiatric Disease and Treatment 2011, 7:519-527
Published Date: 8 September 2011
Narcolepsy: a review
Akintomide GS, Rickards H
Neuropsychiatric Disease and Treatment 2011, 7:507-518
Published Date: 8 September 2011
An in vitro evaluation of guanfacine as a substrate for P-glycoprotein
Gillis NK, Zhu H-J, Markowitz JS
Neuropsychiatric Disease and Treatment 2011, 7:501-505
Published Date: 26 August 2011
Minimally invasive biomarker confirms glial activation present in Alzheimer's disease: a preliminary study
Sailasuta N, Harris K, Tran T, Ross B
Neuropsychiatric Disease and Treatment 2011, 7:495-499
Published Date: 24 August 2011
Psychotherapy and medication management strategies for obsessive-compulsive disorder
Walsh KH, McDougle CJ
Neuropsychiatric Disease and Treatment 2011, 7:485-494
Published Date: 23 August 2011
Moderate alcohol consumption and cognitive risk
Neafsey EJ, Collins MA
Neuropsychiatric Disease and Treatment 2011, 7:465-484
Published Date: 11 August 2011
APRESS: apical regulatory super system, serotonin, and dopamine interaction
Hinz M, Stein A, Uncini T
Neuropsychiatric Disease and Treatment 2011, 7:457-463
Published Date: 5 August 2011
Radioelectric brain stimulation in the treatment of generalized anxiety disorder with comorbid major depression in a psychiatric hospital: a pilot study
Olivieri E, Vecchiato C, Ignaccolo N, Mannu P, Castagna A, Aravagli L, Fontani V, Rinaldi S.
Neuropsychiatric Disease and Treatment 2011, 7:449-455
Published Date: 4 August 2011
Ginkgo biloba extract in the treatment of tinnitus: a systematic review
von Boetticher A
Neuropsychiatric Disease and Treatment 2011, 7:441-447
Published Date: 28 July 2011
A biological pathway linking inflammation and depression: activation of indoleamine 2,3-dioxygenase
Christmas DM, Potokar JP, Davies SJ
Neuropsychiatric Disease and Treatment 2011, 7:431-439
Published Date: 13 July 2011
Stress disorder and PTSD after burn injuries: a prospective study of predictors of PTSD at Sina Burn Center, Iran
Sadeghi-Bazargani H, Maghsoudi H, Soudmand-Niri M, Ranjbar F, Mashadi-Abdollahi H
Neuropsychiatric Disease and Treatment 2011, 7:425-429
Published Date: 13 July 2011
Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia
Chow TW, Graff-Guerrero A, Verhoeff NP, Binns MA, Tang-Wai DF, Freedman M, Masellis M, Black SE, Wilson AA, Houle S, Pollock BG
Neuropsychiatric Disease and Treatment 2011, 7:415-424
Published Date: 13 July 2011
Profile of ezogabine (retigabine) and its potential as an adjunctive treatment for patients with partial-onset seizures
Weisenberg JLZ, Wong M
Neuropsychiatric Disease and Treatment 2011, 7:409-414
Published Date: 7 July 2011
Update on rufinamide in childhood epilepsy
Coppola G
Neuropsychiatric Disease and Treatment 2011, 7:399-407
Published Date: 5 July 2011
Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
Louzã M, Elkis H, Ruschel S, de Oliveira IR, Bressan RA, Belmonte-de-Abreu P, Grabowski H, Appolinário JC
Neuropsychiatric Disease and Treatment 2011, 7:391-398
Published Date: 23 June 2011
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy in an Israeli family
Shahien R, Bianchi S, Bowirrat A
Neuropsychiatric Disease and Treatment 2011, 7:383-390
Published Date: 20 June 2011
Choking risk among psychiatric inpatients
Nagamine T
Neuropsychiatric Disease and Treatment 2011, 7:381-382
Published Date: 20 June 2011
Long-term treatment of bipolar disorder with a radioelectric asymmetric conveyor
Mannu P, Rinaldi S, Fontani V, Castagna A
Neuropsychiatric Disease and Treatment 2011, 7:373-379
Published Date: 15 June 2011
Remembering and forgetting: directed forgetting effect in obsessive-compulsive disorder
Konishi M, Shishikura K, Nakaaki S, Komatsu S, Mimura M
Neuropsychiatric Disease and Treatment 2011, 7:365-372
Published Date: 15 June 2011
Is serum brain-derived neurotrophic factor related to craving for or use of alcohol, cocaine, or methamphetamine?
Hilburn C, Nejtek VA, Underwood WA, Singh M, Patel G, Gangwani P, Forster MJ
Neuropsychiatric Disease and Treatment 2011, 7:357-364
Published Date: 21 June 2011
Investigation of insulin resistance in narcoleptic patients: dependent or independent of body mass index?
Engel A, Helfrich J, Manderscheid N, Musholt PB, Forst T, Pfützner A, Dahmen N
Neuropsychiatric Disease and Treatment 2011, 7:351-356
Published Date: 9 June 2011
Update on treatment options for Lambert–Eaton myasthenic syndrome: focus on use of amifampridine
Lindquist S, Stangel M
Neuropsychiatric Disease and Treatment 2011, 7:341-349
Published Date: 30 May 2011
Role of sublingual asenapine in treatment of schizophrenia
Citrome L
Neuropsychiatric Disease and Treatment 2011, 7:325-339
Published Date: 26 May 2011
Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence
McIntyre R, Yoon J, Jerrell JM, Liauw SS
Neuropsychiatric Disease and Treatment 2011, 7:319-323
Published Date: 25 May 2011
Cost-effectiveness analysis of memantine for moderate-to-severe Alzheimer's disease in the Netherlands
Hoogveldt B, Rive B, Severens J, Maman K, Guilhaume C
Neuropsychiatric Disease and Treatment 2011, 7:313-317
Published Date: 15 June 2011
Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder
Berman R, Thase M, Trivedi M, Hazel JA, Marler S, McQuade R, Carson W, Baker R, Marcus R
Neuropsychiatric Disease and Treatment 2011, 7:303-312
Published Date: 24 May 2011
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
Antonini A, Calandrella D
Neuropsychiatric Disease and Treatment 2011, 7:297-302
Published Date: 15 May 2011
Recurrent major depression, ataxia, and cardiomyopathy: association with a novel POLG mutation?
Verhoeven WMA, Egger JIM, Kremer BPH, de Pont BJHB, Marcelis CLM
Neuropsychiatric Disease and Treatment 2011, 7:293-296
Published Date: 15 May 2011
Risk factors for the development of depression in patients with hepatitis C taking interferon-α
Smith KJ, Norris S, O'Farrelly C, O'Mara SM
Neuropsychiatric Disease and Treatment 2011, 7:275-292
Published Date: 15 May 2011
Physician perception of clinical improvement in children with attention-deficit/hyperactivity disorder: a post hoc comparison of lisdexamfetamine dimesylate and mixed amphetamine salts extended release in a crossover analog classroom study
López F, Scheckner B, Childress A
Neuropsychiatric Disease and Treatment 2011, 7:267-273
Published Date: 6 May 2011
The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder
Pompili M, Venturini P, Innamorati M , Serafini G, Telesforo L, Lester D, Tatarelli R, Girardi P
Neuropsychiatric Disease and Treatment 2011, 7:259-265
Published Date: 6 May 2011
Nondrug-related aspect of treating Ekbom disease, formerly known as restless legs syndrome
Mitchell UH
Neuropsychiatric Disease and Treatment 2011, 7:251-257
Published Date: 6 May 2011
A review of neuroimaging studies of anxiety disorders in China
Chen J, Shi S
Neuropsychiatric Disease and Treatment 2011, 7:241-249
Published Date: 2 May 2011
Impact of extended-release dalfampridine on walking ability in patients with multiple sclerosis
Hayes KC
Neuropsychiatric Disease and Treatment 2011, 7:229-239
Published Date: 28 April 2011
A childhood case of symptomatic essential and psychogenic palatal tremor
Margari F, Giannella G, Lecce PA, Fanizzi P, Toto M, Margari L
Neuropsychiatric Disease and Treatment 2011, 7:223-227
Published Date: 27 April 2011
Prevalence and diagnostic distribution of medically unexplained painful somatic symptoms across 571 major depressed outpatients
Fornaro M, Maremmani I, Canonico PL, Carbonatto P, Mencacci C, Muscettola G, Pani L, Torta R, Vampini C, Parazzini F, Dumitriu A, Perugi G
Neuropsychiatric Disease and Treatment 2011, 7:217-221
Published Date: 21 April 2011
Alleviating neuropsychiatric symptoms in dementia: the effects of Ginkgo biloba extract EGb 761®. Findings from a randomized controlled trial
Bachinskaya N, Hoerr R, Ihl R
Neuropsychiatric Disease and Treatment 2011, 7:209-215
Published Date: 20 April 2011
When neurologist and patient disagree on reasonable risk: new challenges in prescribing for patients with multiple sclerosis
Kachuck NJ
Neuropsychiatric Disease and Treatment 2011, 7:197-208
Published Date: 19 April 2011
Screening for cognitive decline following single known stroke using the Mini-Mental State Examination
Arciniegas DB, Kellermeyer GF, Bonifer NM, Anderson-Salvi KM, Anderson CA
Neuropsychiatric Disease and Treatment 2011, 7:189-196
Published Date: 13 April 2011
Population-based study of acquired cerebellar ataxia in Al-Kharga district, New Valley, Egypt
Farghaly WMA, El-Tallawy HN, Shehata GA, Rageh TA, Abdel Hakeem N, Abo-Elfetoh NM
Neuropsychiatric Disease and Treatment 2011, 7:183-187
Published Date: 5 April 2011
Cognitive behavioral therapy for the treatment of post-traumatic stress disorder: a review
Kar N
Neuropsychiatric Disease and Treatment 2011, 7:167-181
Published Date: 4 April 2011
Status epilepticus in the elderly: differential diagnosis and treatment
Mauricio EA, Freeman WD
Neuropsychiatric Disease and Treatment 2011, 7:161-166
Published Date: 29 March 2011
Current and emerging therapies for the treatment of myasthenia gravis
Renato Mantegazza, Silvia Bonanno, Giorgia Camera, et al
Neuropsychiatric Disease and Treatment 2011, 7:151-160
Published Date: 22 March 2011
Pharmacotherapy for treatment-resistant schizophrenia
Meghan E Mcilwain, Jeff Harrison, Amanda J Wheeler, et al
Neuropsychiatric Disease and Treatment 2011, 7:135-149
Published Date: 17 March 2011
Management of traumatic events: influence of emotion-centered coping strategies on the occurrence of dissociation and post-traumatic stress disorder
Georges Brousse, Benjamin Arnaud, Jordane Durand Roger, et al
Neuropsychiatric Disease and Treatment 2011, 7:127-133
Published Date: 17 March 2011
Performance of Cpred/Cobs concentration ratios as a metric reflecting adherence to antidepressant drug therapy
Yan Feng, Marc R Gastonguay, Bruce G Pollock, et al
Neuropsychiatric Disease and Treatment 2011, 7:117-125
Published Date: 17 March 2011
Psychiatric disorders in primary focal dystonia and in Parkinson’s disease
Fernando MV Dias, Arthur Kummer, Flávia CP Doyle, et al
Neuropsychiatric Disease and Treatment 2011, 7:111-116
Published Date: 14 March 2011
Do neurologists in Germany adhere to the national Parkinson's disease guideline?
Sabrina Schröder, Daniel Kuessner, Guy Arnold, et al
Neuropsychiatric Disease and Treatment 2011, 7:103-110
Published Date: 7 March 2011
Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia
Srihari Gopal, Joris Berwaerts, Isaac Nuamah, et al
Neuropsychiatric Disease and Treatment 2011, 7:93-101
Published Date: 8 March 2011
The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder
Charles L Bowden
Neuropsychiatric Disease and Treatment 2011, 7:87-92
Published Date: 7 March 2011
Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia
Hongyan Zhang, Huafang Li, Liang Shu, et al
Neuropsychiatric Disease and Treatment 2011, 7:77-85
Published Date: 4 March 2011
Brain volumetric measures in alcoholics: a comparison of two segmentation methods
Marlene Oscar-Berman, Janet Song
Neuropsychiatric Disease and Treatment 2011, 7:65-75
Published Date: 27 February 2011
The relationship between insomnia and depressive symptoms: genuine or artifact?
Fadia Isaac, Kenneth Mark Greenwood
Neuropsychiatric Disease and Treatment 2011, 7:57-63
Published Date: 14 February 2011
Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation
Michele Fornaro, Matteo Martino, Florinda Battaglia, et al
Neuropsychiatric Disease and Treatment 2011, 7:51-56
Published Date: 10 February 2011
Comparative efficacy of escitalopram in the treatment of major depressive disorder
Mazen K Ali, Raymond W Lam
Neuropsychiatric Disease and Treatment 2011, 7:39-49
Published Date: 1 February 2011
Treatment of attention deficit hyperactivity disorder with monoamine amino acid precursors and organic cation transporter assay interpretation
Marty Hinz, Alvin Stein, Robert Neff, et al
Neuropsychiatric Disease and Treatment 2011, 7:31-38
Published Date: 26 January 2011
Evidence to practice: treatment of anxiety in individuals with autism spectrum disorders
Russell Lang, Richard Mahoney, Farah El Zein, et al
Neuropsychiatric Disease and Treatment 2011, 7:27-30
Published Date: 25 January 2011
Clinical outcomes of long-acting injectable risperidone in patients with schizophrenia: six-month follow-up from the Electronic Schizophrenia Treatment Adherence Registry in Latin America
Rogelio Apiquian, Rodrigo Córdoba, Mario Louzã
Neuropsychiatric Disease and Treatment 2011, 7:19-26
Published Date: 22 December 2010
The societal costs of insomnia
Alan G Wade
Neuropsychiatric Disease and Treatment 2011, 7:1-18
Published Date: 20 December 2010